Company profile: Gennao Bio
1.1 - Company Overview
Company description
- Provider of genetic medicines developing targeted nucleic acid therapeutics for muscle diseases, featuring GMAB, a non-viral, cell-penetrating antibody technology that delivers nucleic acid payloads into cells targeting cancer and skeletal muscle disorders, and GMAB ADC for solid tumors, an antibody-drug conjugate demonstrated in preclinical studies to deliver cytotoxic drugs directly to tumor cells.
Products and services
- GMAB ADC for Solid Tumors: A preclinical-stage antibody-drug conjugate built on GMAB that directs cytotoxic payloads precisely to solid tumor cells, demonstrating tumor-targeted drug delivery in preclinical studies
- GMAB Technology: A non-viral, cell-penetrating antibody platform that transports nucleic acid payloads directly into cells, enabling targeted intervention for cancers and skeletal muscle disorders with intracellular payload delivery
- Targeted Nucleic Acid Therapeutics for Muscle Diseases: Custom-engineered nucleic acid medicines developed to precisely address muscle pathology, aiming to cure muscle diseases by targeting diseased muscle with therapeutic payloads
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gennao Bio
Broncus Medical
HQ: United States
Website
- Description: Provider of minimally invasive medical devices for emphysema and other lung diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Broncus Medical company profile →
Epigenomics
HQ: Germany
Website
- Description: Provider of molecular diagnostics, developing and commercializing in vitro cancer diagnostic tests to detect cancer at early stages using body fluids such as blood plasma; offerings include Epi proColon, a blood test for colorectal cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epigenomics company profile →
NeoGenomics
HQ: United States
Website
- Description: Provider of cancer testing and partnership programs for pathologists and oncologists, offering diagnostic services (flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers), anatomic pathology (histology, tissue staining, digital pathology), NGS panels including Neo Comprehensive™ – Heme Cancers, Early-stage NSCLC Panel, InVisionFirst®-Lung, and pharma services for biomarker discovery, clinical trials, and companion diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoGenomics company profile →
Infinity Pharmaceuticals
HQ: United States
Website
- Description: Provider of drug discovery and development focused on medicines for the treatment of cancer and related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infinity Pharmaceuticals company profile →
Verastem
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting RAS/MAPK pathway–driven cancers, developing avutometinib, a RAF/MEK clamp designed to block RAF and MEK signaling in the RAS pathway, and defactinib, a FAK inhibitor used with avutometinib to block compensatory FAK activation and enhance tumor growth blockade.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verastem company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gennao Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gennao Bio
2.2 - Growth funds investing in similar companies to Gennao Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gennao Bio
4.2 - Public trading comparable groups for Gennao Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →